Valiant Laboratories Ltd
Valiant Laboratories Ltd (VALIANTLAB) last reported results for the quarter ended Jun 2026, with sales of ₹115 crore and net profit of ₹21 crore. The stock last traded at ₹126, a market capitalisation of ₹687 crore, on a P/E of 42.9. Over the past 52 weeks the stock has ranged between ₹49.5 and ₹132. Figures are as of 6 Oct 2026 and are not real time.
Valiant Laboratories Ltd share price and key metrics
- Current price
- ₹126
- Market cap
- ₹687 cr
- Stock P/E
- 42.9
- Book value
- ₹57.2
- ROE
- -1.20%
- ROCE
- 0.75%
- Dividend yield
- 0.00%
- 52w high / low
- 132/49.5
Metrics as of 6 Oct 2026. Not real time.
Track Valiant Laboratories Ltd
Cruxal reads every Valiant Laboratories Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Valiant Laboratories Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -11%
- TTM
- 90%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 12208%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -8%
- 1 Year
- 52%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -1%
- Last Year
- -1%
Valiant Laboratories Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹115 cr, up 144.7% from ₹47 cr a year earlier. Net profit was ₹21 cr, up 950.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 21 | 35 | 58 | 47 | 46 | 52 | 92 | 115 |
| Expenses | 28 | 35 | 54 | 44 | 46 | 53 | 87 | 86 |
| Operating profit | -7 | 1 | 4 | 2 | 0 | -1 | 5 | 29 |
| OPM % | -31% | 1.8% | 7% | 5% | 0.2% | -1.7% | 5% | 25% |
| Other income | 3 | 2 | -2 | 1 | 1 | 1 | 0 | 1 |
| Interest | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Profit before tax | -4 | 2 | 1 | 2 | 0 | -3 | 1 | 26 |
| Tax % | 21% | -44% | 26% | 26% | 25% | 136% | -68% | 19% |
| Net profit | -5 | 2 | 1 | 2 | 0 | -7 | 2 | 21 |
| EPS (₹) | -0.87 | 0.43 | 0.13 | 0.34 | 0.04 | -1.30 | 0.32 | 3.88 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Valiant Laboratories Ltd annual results
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|
| Sales | 334 | 182 | 133 | 237 | 306 |
| Operating profit | 35 | -8 | -5 | 6 | 33 |
| OPM % | 11% | -4.6% | -3.5% | 2.7% | 11% |
| Net profit | 29 | 0 | -2 | -3 | 16 |
| EPS (₹) | 7.13 | 0.06 | -0.41 | -0.60 | 2.94 |
TTM is the trailing twelve months to the most recent quarter.
Valiant Laboratories Ltd balance sheet
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Equity capital | 33 | 43 | 43 | 54 |
| Reserves | 68 | 193 | 191 | 257 |
| Borrowings | 60 | 77 | 122 | 46 |
| Other liabilities | 52 | 29 | 45 | 107 |
| Total liabilities | 213 | 343 | 401 | 464 |
| Fixed assets | 48 | 50 | 48 | 227 |
| CWIP | 1 | 43 | 156 | 6 |
| Investments | 34 | 38 | 0 | 28 |
| Other assets | 130 | 212 | 197 | 202 |
| Total assets | 213 | 343 | 401 | 464 |
As reported by the company. Total assets equal total liabilities by construction.
Valiant Laboratories Ltd cash flow
| ₹ crore | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Cash from operations | 56 | 2 | 1 | -10 |
| Cash from investing | -55 | -144 | -53 | 7 |
| Cash from financing | -1 | 152 | 45 | 2 |
| Net cash flow | -0 | 10 | -7 | -1 |
| Free cash flow | 18 | -44 | -112 | -45 |
| CFO / operating profit | 185% | -11% | 25% | -147% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Valiant Laboratories Ltd operating ratios
| Per year | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| ROCE % | — | -2% | -1% | 1% |
| Debtor days | 97 | 92 | 197 | 144 |
| Inventory days | 17 | 22 | 13 | 84 |
| Days payable | 62 | 56 | 128 | 174 |
| Cash conversion cycle | 52 | 57 | 82 | 54 |
| Working capital days | 70 | 106 | 156 | 156 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Valiant Laboratories Ltd shareholding pattern
Promoters held 74.94% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.00% and DIIs 0.00%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% | 74.94% |
| FIIs | 0.00% | 0.00% | 0.64% | 0.63% | 0.02% | 0.01% | 0.20% | 0.00% |
| DIIs | 0.00% | 0.00% | 0.00% | 0.46% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public | 25.06% | 25.06% | 24.42% | 23.97% | 25.05% | 25.05% | 24.87% | 25.06% |
| No. of shareholders | 15,189 | 15,692 | 15,036 | 14,432 | 15,075 | 14,910 | 14,657 | 14,341 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Cruxal coverage of Valiant Laboratories Ltd
Valiant Laboratories Ltd corporate filings
- Closure of Trading Window for declaration of Financial Results for the quarter and half year ended September 30, 2026.Insider Trading / SASTlow impact
- Scrutinizer''s Report and Voting Results of 5th AGM of Valiant Laboratories Limited.AGM/EGMmedium impact
- Valiant Laboratories Limited concludes 5th Annual General Meeting; highlights debt-free status and subsidiary operational progressAGM/EGMlow impact
Cruxal's analysis: Valiant Laboratories Limited held its 5th Annual General Meeting on September 28, 2026…
Read the full analysis - Valiant Laboratories Limited to acquire stake in AMPYR Renewable Energy for group captive solar power procurementCompany Updatemedium impact
Cruxal's analysis: Valiant Laboratories Limited has approved an investment of up to 70 lakh INR to acquire a…
Read the full analysis - Valiant Laboratories Ltd announces dispatch of Annual Report and notice for 5th Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Valiant Laboratories Ltd has completed the dispatch of its Annual Report for the…
Read the full analysis - Valiant Laboratories Limited receives IND BBB/Stable/IND A2 credit rating for bank loan facilities of 56 croreCompany Updatelow impact
Cruxal's analysis: Valiant Laboratories Limited has been assigned a credit rating of IND BBB/Stable/IND A2…
Read the full analysis - Valiant Laboratories Ltd issues routine letter to shareholders under SEBI LODR Regulation 36(1)(b)Company Updatelow impact
Cruxal's analysis: Valiant Laboratories has issued a formal letter to shareholders in compliance with…
Read the full analysis - Valiant Laboratories Limited Announces FY 2025-26 Annual Report and Notice of 5th Annual General MeetingAGM/EGMhigh impact
Cruxal's analysis: Valiant Laboratories Limited has released its Annual Report for FY 2025-26, highlighting…
Read the full analysis - Valiant Laboratories Ltd releases Annual Report for FY 2025-26Otherslow impact
Cruxal's analysis: Valiant Laboratories has filed its Annual Report for the financial year 2025-26. The…
Read the full analysis - Valiant Laboratories Limited schedules 5th Annual General Meeting for September 28, 2026Company Updatelow impact
Cruxal's analysis: Valiant Laboratories Limited has issued a formal notice for its 5th Annual General…
Read the full analysis - Valiant Laboratories Reports Strong Q1 FY27 Financials with Significant Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Valiant Laboratories Limited has announced its audited financial results for the quarter…
Read the full analysis - Valiant Laboratories Ltd releases Monitoring Agency Report for quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Valiant Laboratories has filed its Monitoring Agency Report for the quarter ended June…
Read the full analysis - Valiant Laboratories Ltd announces opening of new corporate officeCompany Updatelow impact
Cruxal's analysis: Valiant Laboratories Ltd has formally announced the opening of a new corporate office…
Read the full analysis - Valiant Laboratories Ltd announces proposal to change registered office addressCompany Updatelow impact
Cruxal's analysis: Valiant Laboratories Ltd has announced a proposal to change its registered office…
Read the full analysis - Valiant Laboratories to inject 60 crore into wholly owned subsidiary VASPL for working capital and capital base strengtheningCompany Updatemedium impact
Cruxal's analysis: Valiant Laboratories Limited has announced an additional investment of up to 60 crore in…
Read the full analysis - Valiant Laboratories Reports Strong Q1 FY27 Financial Results with Significant Profit GrowthBoard Meetinghigh impact
Cruxal's analysis: Valiant Laboratories Limited has announced its audited financial results for the quarter…
Read the full analysis - Valiant Laboratories Limited schedules Board Meeting for August 10, 2026, to approve Q1 FY27 financial resultsBoard Meetinglow impact
Cruxal's analysis: Valiant Laboratories Limited has formally intimated the stock exchanges regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.